Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 2Withdrawn 1

Sponsor Class

OTHER 3NIH 2INDUSTRY 2

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2

Conditions

Kidney Neoplasms 1Carcinoma, Renal Cell 1Advanced Cancers 1

Interventions

Cyclophosphamide 2040Radiotherapy 1854Cisplatin 1820Carboplatin 1530Gemcitabine 1432Paclitaxel 1289Bevacizumab 1267Docetaxel 1200pembrolizumab 1196Oxaliplatin 1157Capecitabine 1140Fluorouracil 1059Dexamethasone 971Rituximab 918Nivolumab 908Magnetic Resonance Spectroscopy 858Etoposide 839Doxorubicin 823Drug Therapy 789Radiosurgery 774Irinotecan 774Cytarabine 736fludarabine 714Leucovorin 674Lenalidomide 608fludarabine phosphate 564Temozolomide 552Filgrastim 540Radiation 539Cetuximab 535

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Interventional × AH 111585 × Clear all
NCT01492192 2017-11-01

RGD-PET-CT in Cancer Angiogenesis

Oxford University Hospitals NHS Trust

Phase 2 Terminated
10 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT01961583 2016-03-01

[18F]Fluciclatide PET Imaging of Pazopanib Response

Asan Medical Center

Phase 2 Terminated
12 enrolled
Genitourinary

Kidney Neoplasms

NCT02193672 2014-07-18

A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡